GLTO_OUT_1 [2025-03-21 10:50:55 -0400] 1819 Bytes | 533 tokens | Cum: 533 tkns (6.66% of 8k)
==========================================================================

Booyah, my friends! It's already 10:50:53 AM on Fri Mar 21, 2025 -0400, and I've got my eyes locked on Galecto (GLTO), pushing up to 5.3915 from 4.14. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

Here's the first list of news for Galecto:

C1 - Mar-19-25 04:45PM - Galecto Reports Full-Year 2024 Financial Results
C2 - Feb-06-25 08:00AM - Galecto to Participate in Upcoming Investor Conferences
C3 - Nov-14-24 09:55AM - Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
C4 - Nov-01-24 08:30AM - Galecto Reports Third Quarter 2024 Financial Results
C5 - Oct-18-24 08:15AM - Galecto price target raised to $10 from $9 at Oppenheimer
C6 - Oct-15-24 08:30AM - Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler
C7 - Oct-07-24 08:45AM - Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
C8 - Aug-28-24 09:00AM - Galecto Announces Reverse Stock Split

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Galecto (GLTO)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

GLTO_OUT_3 [2025-03-21 10:50:58 -0400] 1044 Bytes | 298 tokens | Cum: 833 tkns (10.41% of 8k)
==========================================================================

Showing C1 (chunk 1 of 8): C1:
**Galecto Reports Full-Year 2024 Financial Results**
Date: Mar-19-25 04:45PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/19/3045829/0/en/Galecto-Reports-Full-Year-2024-Financial-Results.html

March 19, 2025 16:45 ET| Source:Galecto, Inc.Galecto, Inc.

BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial results for the quarter and year ended December 31, 2024.

“A significant moment for Galecto in 2024 was the completion of our strategic review, which solidified our commitment to advancing innovative oncology therapies,” said Dr. Hans Schambye, CEO of Galecto. “The acquisition of global rights to GB3226 provides us with an opportunity to develop a unique approach to AML that

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

GLTO_OUT_5 [2025-03-21 10:51:03 -0400] 1044 Bytes | 215 tokens | Cum: 1050 tkns (13.12% of 8k)
==========================================================================

Showing C1 (chunk 2 of 8): has the potential to significantly improve outcomes for the AML patient population. GB3226 has shown strong potential in preclinical studies, showing activity against a range of AML-driving mutations, including those commonly associated with resistance and relapse. With its dual mechanism of action, GB3226 has the potential to provide rapid therapeutic effect via inhibition of FLT3 and promote sustained response through inhibition of ENL-YEATS.”

Dr. Schambye continued, “We are focused on moving GB3226 into clinical development as quickly as possible while maintaining our commitment to advancing transformative treatments for cancer and liver diseases. With a strengthened pipeline and a clear strategic focus, we look forward to advancing these promising therapies for patients in need.”

Cash and cash equivalents as of December 31, 2024 were approximately $14.2 million. The Company antici

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

GLTO_OUT_7 [2025-03-21 10:51:04 -0400] 841 Bytes | 267 tokens | Cum: 1319 tkns (16.49% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-19T20:45:00Z - Galecto Reports Full-Year 2024 Financial Results...
A2 - 2025-03-19T20:58:06Z - Galecto Reports Full-Year 2024 Financial Results By Investing.com...
A3 - 2025-03-19T20:51:48Z - Galecto Reports Full-Year 2024 Financial Results...
A4 - 2025-03-19T20:57:02Z - Galecto Reports Full-Year 2024 Financial Results | Taiwan News | Mar. 20, 2025 04:45...
A5 - 2025-03-19T20:53:16Z - Galecto GAAP EPS of -$18.53 misses by $2.62 (NASDAQ:GLTO)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

GLTO_OUT_9 [2025-03-21 10:51:05 -0400] 1038 Bytes | 272 tokens | Cum: 1593 tkns (19.91% of 8k)
==========================================================================

Showing A1 (chunk 1 of 8): A1:
**Galecto Reports Full-Year 2024 Financial Results**Date: 2025-03-19Source: {'uri': 'forextv.com', 'dataType': 'news', 'title': 'ForexTV'}URL: https://forextv.com/galecto-reports-full-year-2024-financial-results/BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial results for the quarter and year ended December 31, 2024.

"A significant moment for Galecto in 2024 was the completion of our strategic review, which solidified our commitment to advancing innovative oncology therapies," said Dr. Hans Schambye, CEO of Galecto. "The acquisition of global rights to GB3226 provides us with an opportunity to develop a unique approach to AML that has the potential to significantly improve outcomes for the AML patient popul

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

GLTO_OUT_11 [2025-03-21 10:51:07 -0400] 938 Bytes | 306 tokens | Cum: 1901 tkns (23.76% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-06T13:00:00Z - Galecto to Participate in Upcoming Investor Conferences
B2 - 2024-10-07T12:45:00Z - Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
B3 - 2024-05-01T20:01:00Z - Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
B4 - 2024-02-14T17:00:05Z - Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?
B5 - 2024-02-14T10:48:00Z - New Strong Buy Stocks for February 14th
B6 - 2024-01-09T21:57:30Z - What Makes Galecto, Inc. (GLTO) a New Strong Buy Stock

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GLTO_OUT_13 [2025-03-21 10:51:11 -0400] 640 Bytes | 163 tokens | Cum: 2066 tkns (25.82% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Galecto to Participate in Upcoming Investor Conferences**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/06/3021967/0/en/Galecto-to-Participate-in-Upcoming-Investor-Conferences.htmlGalecto, a clinical-stage biotechnology company, announced its participation in upcoming investor conferences, including the Oppenheimer 35th Annual Healthcare Life Sciences Conference, Leerink Partners Global Healthcare Conference, and 37th Annual ROTH Conference.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

GLTO_OUT_15 [2025-03-21 10:51:13 -0400] 1087 Bytes | 298 tokens | Cum: 2418 tkns (30.23% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-19 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The following information should be read in conjunction with the audited CONS financial statements and notes thereto for the year ended December 31, 2024 included in this Annu...

S6 - 2024-11-01 10-Q PART IFINANCI AL INFO

Item 1. Financi al Stmnts.

GALECTO, INC.

Condensed Consolidat ed Balance Sheets

(in thousands, except share and per share amounts)

September 30,

December 31,

Assets

(unaudited)

Curr assets

Cash and cash equiv

$

19...

S7 - 2024-10-07 8-K Item 1.01 Entry into a Material Definitive Agrmt.

Asset Purchase Agrmt

On October 7, 2024, Galecto, Inc. (the Company ) and Bridge Medicines LLC, a Delaware limited liability company ( Bridge Medicines ), entered into an Asset Purchase Agrmt (the Purchase Agreemen...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GLTO_OUT_17 [2025-03-21 10:51:14 -0400] 1038 Bytes | 208 tokens | Cum: 2628 tkns (32.85% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

The following information should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2024 included in this Annual Report on Form 10-K. This discussion and analysis and other parts of this Annual Report on Form 10-K contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth herein and in other SEC filings.

Overview

We are a clinical-stage biotechnology comp

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

GLTO_OUT_19 [2025-03-21 10:51:16 -0400] 1038 Bytes | 216 tokens | Cum: 2846 tkns (35.58% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): any developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and liver diseases. Our strategy is to focus on diseases without disease-modifying treatment options and where there is a high unmet medical need.

In September 2023, we announced a corporate restructuring that resulted in a substantial reduction of our workforce and that we had initiated a process to evaluate strategic alternatives. On October 7, 2024, we announced that we had completed our strategic alternative review process and determined to focus on oncology and severe liver diseases. In connection with this announcement, we announced that we had entered into the Bridge Purchase Agreement with Bridge Medicines, pursuant to which we acquired global rights to Bridge Medicines BRM-1420 program, a novel dual ENL-YEATS and FLT3 inhibitor for multiple gene

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

GLTO_OUT_21 [2025-03-21 10:51:33 -0400] 5988 Bytes | 1712 tokens | Cum: 4560 tkns (57.00% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+---------------------+-----------------------+------------------------+----------------------+-----------------------+
| Volume: 954,074 | SMA50: 19.40% | Market Cap: 7.39M | Option/Short: No / Yes | Sales past 5Y: 0.00% | Sales Surprise: - |
+--------------------+---------------------+-----------------------+------------------------+----------------------+-----------------------+
| Avg Volume: 17.46K | SMA200: -35.78% | Shs Outstand: 1.25M | Short Float: 1.61% | Employees: 13 | EPS Surprise: -72.73% |
+--------------------+---------------------+-----------------------+------------------------+----------------------+-----------------------+
| Rel Volume: 262.25 | Perf Week: 38.18% | Shs Float: 1.14M | Short Ratio: 1.05 | Debt/Eq: 0.00 | P/E: - |
+--------------------+---------------------+-----------------------+------------------------+----------------------+-----------------------+
| RSI (14): 70.69 | Perf Month: 15.62% | Inst Own: 3.20% | Short Interest: 0.02M | Sales Y/Y TTM: - | Earnings: Mar 19 AMC |
+--------------------+---------------------+-----------------------+------------------------+----------------------+-----------------------+
| ATR (14): 0.40 | Perf Quarter: 6.80% | Insider Own: 13.49% | Beta: 1.15 | ROE: -72.61% | |
+--------------------+---------------------+-----------------------+------------------------+----------------------+-----------------------+
| SMA20: 31.34% | Index: - | Insider Trans: -1.15% | Sales Q/Q: - | ROI: -101.14% | |
+--------------------+---------------------+-----------------------+------------------------+----------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Galecto, Inc. (GLTO) by Schambye Hans T. (Chief Executive Officer) on 2025-01-03
- Common Stock: 2640 shares at $N/A (D)
- Common Stock: 1341 shares at $5.6 (D) Footnote: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person.
- Restricted Stock Units: 2640 shares at $0 (D)
- Stock Option (right to buy): 16400 shares at $0 (D)

Inside Trans: Galecto, Inc. (GLTO) by Kronmiller Matthew (EVP Strategy and CBO) on 2025-01-03
- Stock Option (right to buy): 6000 shares at $0 (D)

Inside Trans: Galecto, Inc. (GLTO) by Firmani Lori (Interim CFO) on 2025-01-03
- Common Stock: 726 shares at $N/A (D)
- Common Stock: 261 shares at $5.63 (D) Footnote: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person.
- Restricted Stock Units: 726 shares at $0 (D)
- Stock Option (right to buy): 5000 shares at $0 (D)

Inside Trans: Galecto, Inc. (GLTO) by Winslow Garrett (General Counsel) on 2025-01-03
- Common Stock: 1320 shares at $N/A (D)
- Common Stock: 471 shares at $5.6 (D) Footnote: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person.
- Restricted Stock Units: 1320 shares at $0 (D)
- Stock Option (right to buy): 6000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: Galecto, Inc. Common Stock
Market Cap: 5452334.46
Shares Outstanding: 1316989
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 844000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -21439000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 5.41
Average Volume: 69795.0
30-Day High: 5.41
30-Day Low: 3.97

[Detailed Financials: TTM 2024]
- Total Assets: $17,132,000.0
- Total Liabilities: $1,301,000.0
- Total Equity: $15,831,000.0
- Current Assets: $16,839,000.0
- Current Liabilities: $1,197,000.0

[Income Statement: TTM 2024]
- Revenue: $844,000.00
- Net Income: $-21,439,000.0
- Operating Income: $-22,260,000.0
- Earnings Per Share (EPS): -18.53

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $317,000

[Detailed Financials: FY 2024]
- Total Assets: $17,132,000.0
- Total Liabilities: $1,301,000.0
- Total Equity: $15,831,000.0
- Current Assets: $16,839,000.0
- Current Liabilities: $1,197,000.0

[Income Statement: FY 2024]
- Revenue: $844,000.00
- Net Income: $-21,439,000.0
- Operating Income: $-22,260,000.0
- Earnings Per Share (EPS): -18.53

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $317,000
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

GLTO_OUT_23 [2025-03-21 10:51:36 -0400] 676 Bytes | 167 tokens | Cum: 5050 tkns (63.12% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

GLTO_IN_25 [2025-03-21 10:51:36 -0400] 126 Bytes | 29 tokens | Cum: 5107 tkns (63.84% of 8k)
==========================================================================

====================================
[2025-03-21 07:51:36] # Analysis Completed
Elapsed Time: 43.41 seconds